Bruker Announces Two 1.2 GHz NMR Systems Orders from the UK
March 17 2023 - 6:00AM
Business Wire
Universities of Warwick and Birmingham to
receive 1.2 GHz NMRs for Enabling Life-Science and Green-Tech
Research throughout the United Kingdom
Bruker announces that the United Kingdom is expanding its
fundamental research infrastructure with recent orders for two
1.2 GHz Avance™ nuclear magnetic resonance (NMR)
spectrometers for the University of Warwick and the University of
Birmingham. Each institution already has a Bruker 1.0 GHz NMR
spectrometer and will advance their capabilities further for
research into the materials properties for energy storage and
biofuels, as well as into structures and interactions of
biomolecules such as proteins, nucleic acids, carbohydrates,
lipids, and metabolites. System installations are expected in 2025,
and scientists from across the UK will have access, while students
can gain experience at the forefront of research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230317005016/en/
1.2 GHz Avance™ nuclear magnetic
resonance (NMR) spectrometer (Photo: Business Wire)
The University of Warwick 1.2 GHz NMR will advance research in
improved plant biofuels, batteries, and solar cells by studying
molecular structures and dynamics of advanced materials. The
scientific insights gained help improve efficiency and durability
of renewable energy technologies, and to develop novel
materials.
Professor Steven Brown from the University of Warwick
Solid-State NMR Group commented: “The linking of the new 1.2 GHz
spectrometer at the University of Warwick to the 850 MHz and 1 GHz
systems of the UK High-Field Solid-State NMR Facility will enable
UK scientists to push forward frontiers in diverse fields from
batteries and catalysts to pharmaceuticals and plant biomass.”
The University of Birmingham will utilize the increased
sensitivity and resolution of 1.2 GHz NMR to advance research in
functional and structural biology, and drug discovery. Researchers
will study the structure, function, interactions and pathways of
proteins and other biomolecules. As an example, they will study the
structure of enzymes involved in antibiotic resistance, which could
help in development of new antibiotics.
Teresa Carlomagno, Professor and Academic Lead of HWB-NMR
University of Birmingham stated: “NMR plays a unique and key role
in the understanding of molecular mechanisms in health and disease
contexts. This is in particular because of its ability to deal with
dynamics and disorder, which are often responsible for the
regulation of these mechanisms. We are excited to add the 1.2 GHz
NMR from Bruker to our research infrastructure and push our
biomolecular research beyond current boundaries.”
Dr. Falko Busse, President of the Bruker BioSpin Group,
commented: "I am pleased to announce two orders for 1.2 GHz NMRs
from the Universities of Warwick and Birmingham. Not only does
GHz-class NMR advance life science research, but GHz-class NMR also
advances research in batteries, biofuels, and renewable energy.
Bruker supports the UK science community and looks forward to many
groundbreaking discoveries.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230317005016/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 663-3660 x1479 E: Investor.Relations@bruker.com
Media Contact: Markus Ziegler Sr. Director and Head of
Group Marketing Bruker BioSpin T: +49 172 3733531 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024